grant
Leukotriene B4 Regulation in Heart
Organization UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHLocation SALT LAKE CITY, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2029
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAccelerationAction PotentialsAdult-Onset Diabetes MellitusAnabolismAnti-Arrhythmia AgentsAnti-Arrhythmia DrugsAnti-ArrhythmicsArrhythmiaBLT1BLTRBiophysicsCMKRL1CardiacCardiac ArrhythmiaCardiac ChronotropismCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCaviaCell Communication and SignalingCell SignalingClinical ResearchClinical StudyClinical TreatmentClinical TrialsDataDefectDevelopmentDiabetes MellitusDiabetic mouseDrug TargetingDrugsElectrophysiologyElectrophysiology (science)EthersFDA approvedFRETFluorescence Resonance Energy TransferFutureFörster Resonance Energy TransferG Protein-Coupled Receptor 16GPR16GenesGeneticGoalsGuinea PigsGuinea Pigs MammalsHealthHeartHeart ArrhythmiasHeart RateHeart VascularHigh PrevalenceHumanImpairmentIn VitroInAsIndividualInflammatoryInterventionIntracellular Communication and SignalingIon ChannelIonic ChannelsIschemiaKetosis-Resistant Diabetes MellitusKnock-outKnockoutKnowledgeLTB4LTB4 ReceptorsLTB4RLTB4R geneLTB4R1LabelLeukotriene B-4Leukotriene B4Leukotriene B4 G Protein-Coupled ReceptorLeukotriene B4 ReceptorLeukotriene B4 ReceptorsLeukotrienesLifeMalignantMalignant - descriptorMaturity-Onset Diabetes MellitusMedicationMembrane ChannelsMetabolicModelingModern ManMolecularMuscle CellsMyocardial depressionMyocardial dysfunctionMyocardiumMyocytesNIDDMNeurophysiology / ElectrophysiologyNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusOpticsOutcomeP2RY7P2Y7Pathway interactionsPatientsPharmaceutical PreparationsPhenotypePilot ProjectsPreventionProteinsPurinergic Receptor P2Y, G Protein-Coupled, 7Purinoceptor P2Y7Q-DotQuantum DotsReceptor InhibitionReceptor SignalingRegulationReperfusion TherapyReportingResearchRiskRisk ReductionScienceSignal TransductionSignal Transduction SystemsSignalingSlow-Onset Diabetes MellitusStable Diabetes MellitusSurfaceT2 DMT2DT2DMTherapeuticTorsades de PointesType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesVentricle RemodelingVentricularVentricular ArrhythmiaVentricular Cardiac RemodelingVentricular Myocardial RemodelingVentricular Remodelingadult onset diabetesarrhythmic agentbiological signal transductionbiophysical foundationbiophysical principlesbiophysical sciencesbiosynthesiscardiac dysfunctioncardiac musclecirculatory systemclinical developmentclinical interventionclinical therapydensitydevelopmentaldiabetesdiabetes mouse modeldrug/agentelectrophysiologicalevidence baseexpectationexperimentexperimental researchexperimental studyexperimentsguinea pig modelheart cellheart dysfunctionheart musclehuman modelindium arsenideinhibitorinnovateinnovationinnovativeinsightketosis resistant diabeteslipid mediatormaturity onset diabetesmodel of humanmouse modelmurine modelmyocardial remodelingnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-diabeticnondiabeticnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyopticalpathwaypharmacologicpilot studypre-clinicalpreclinicalpreventpreventingreconstructionreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskreperfusionresponserisk-reducingsudden cardiac deathtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentthree dimensionaltooltraffickingtrial regimentrial treatmenttype 2 DMtype II DMtype two diabetes
Description preview
PROJECT ABSTRACT
Patients with type 2 diabetes (T2DM) are at increased risk (~50%) relative to non-diabetic individuals
of suffering sudden cardiac death (SCD), most often due to fatal ventricular arrhythmias such as torsades de
pointes (TdP). However, the underlying molecular mechanisms are unknown. Therefore, there is the critical
need to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click